Latest news

• Poseida gets Novartis backing for myleoma CAR-T challenger

  San Diego firm joins crowded field. Gene-engineering specialist Poseida Therapeutics is launching its own challenger into the crowded CAR-T pipeline for multiple myeloma, and has just gained backing from ... Poseida’s suite of proprietary gene editing

• CAR-Ts take centre stage as ASH18 comes to a close

  Another anti-BCMA player – Poseida Therapeutics – presented preliminary data on 19 myeloma patients who had a median of six prior lines of therapy.

• BCMA in the spotlight as ASH abstracts drop

  Biotech, Poseida Therapeutics, CARsgen Therapeutics and Memorial Sloan Kettering Cancer Centre showing impressive efficacy results in multiple myeloma.

• J&J buys into Alligator's immuno-oncology candidate

  Earlier this week, J&J licensed rights to a technology used in the development of another hot area in immuno-oncology - chimeric antigen receptor therapies (CAR-T) to Poseida Therapeutics. ... Poseida wants to screen the molecules for activity against